Overview

P4 (Pregabalin for Peripheral Posttraumatic Pain)

Status:
Completed

Trial end date:
2008-05-01

Target enrollment:
0

Participant gender:
All

Summary

To evaluate the efficacy of pregabalin compared to placebo in the treatment of posttraumatic peripheral neuropathic pain

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatments:

Pregabalin

Criteria

Inclusion Criteria:

- Diagnosis of Posttraumatic Peripheral Neuropathic Pain (NeP) syndrome, including
post-surgical NeP, NeP due to peripheral nerve injury, and phantom limb pain,
confirmed by a qualified pain specialist and persisting for a minimum of 3 months
following the traumatic event

Exclusion Criteria:

- Subjects whose posttraumatic neuropathic pain is due to Complex Regional Pain Syndrome
(CRPS, Type I or Type II)

- NeP not due to trauma, and not peripheral pain